Maite Solas

List of Publications by Year
in descending order

38 papers	2,447 citations	304701 22 h-index	315719 38 g-index
43 all docs	43 docs citations	43 times ranked	4788 citing authors

#	Article	IF	Citations
1	Dysbiosis and Alzheimerâ€™s Disease: Cause or Treatment Opportunity?. Cellular and Molecular Neurobiology, 2022, 42, 377-387.	3.3	24
2	Brain Metabolic Alterations in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 3785.	4.1	28
3	Trimethylamine N-oxide (TMAO) drives insulin resistance and cognitive deficiencies in a senescence accelerated mouse model. Mechanisms of Ageing and Development, 2022, 204, 111668.	4.6	16
4	Expression of Endothelial NOX5 Alters the Integrity of the Blood-Brain Barrier and Causes Loss of Memory in Aging Mice. Antioxidants, 2021, 10, 1311.	5.1	11
5	5-HT7 receptors in Alzheimer's disease. Neurochemistry International, 2021, 150, 105185.	3.8	12
6	Biomarkers in Alzheimerâ€™s disease. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 27-37.	0.2	13
7	Astrocytic GLUT1 ablation improves systemic glucose metabolism and promotes cognition. Alzheimer's and Dementia, 2021, 17, e058650.	0.8	2
8	GLUT12 Expression in Brain of Mouse Models of Alzheimerâ€™s Disease. Molecular Neurobiology, 2020, 57, 798-805.	4.0	14
9	Reduced Adrenomedullin Parallels Microtubule Dismantlement in Frontotemporal Lobar Degeneration. Molecular Neurobiology, 2018, 55, 9328-9333.	4.0	1
10	Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice. International Journal of Pharmaceutics, 2018, 543, 245-256.	5.2	11
11	Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients, 2018, 10, 1398.	4.1	403
12	Interactions Between Age, Diet, and Insulin and Their Effect on Cognition. , 2018, , 223-238.		0
13	Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 5177-5183.	4.0	21
14	Serotonin 5-HT6 Receptor Antagonists in Alzheimerâ€™s Disease: Therapeutic Rationale and Current Development Status. CNS Drugs, 2017, 31, 19-32.	5.9	82
15	Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions. Current Opinion in Pharmacology, 2017, 37, 87-92.	3.5	119
16	Exploring Pharmacological Mechanisms of Lavender (Lavandula angustifolia) Essential Oil on Central Nervous System Targets. Frontiers in Pharmacology, 2017, 8, 280.	3.5	169
17	Downâ€regulation of glutamatergic terminals (VGLUT1) driven by AÎ² in Alzheimer's disease. Hippocampus, 2016, 26, 1303-1312.	1.9	32
18	JNK: A Putative Link Between Insulin Signaling and VGLUT1 in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 50, 963-967.	2.6	3

#	Article	IF	Citations
19	Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches. Trends in Pharmacological Sciences, 2016, 37, 575-593.	8.7	36
20	Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity. Cell, 2016, 165, 882-895.	28.9	167
21	Lipoic acid improves neuronal insulin signalling and rescues cognitive function regulating VGlut1 expression in high-fat-fed rats: Implications for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 511-517.	3.8	20
22	Resistin, an Adipokine with Non-Generalized Actions on Sympathetic Nerve Activity. Frontiers in Physiology, 2015, 6, 321.	2.8	28
23	Venlafaxine reverses decreased proliferation in the subventricular zone in a rat model of early life stress. Behavioural Brain Research, 2015, 292, 79-82.	2.2	4
24	c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2015, 6, 321.	3.5	284
25	Treatment Options in AlzheimerÂ´s Disease: The GABA Story. Current Pharmaceutical Design, 2015, 21, 4960-4971.	1.9	103
26	The paradox of neuronal insulin action and resistance in the development of agingâ€associated diseases. Alzheimer's and Dementia, 2014, 10, S3-11.	0.8	66
27	CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiology of Aging, 2013, 34, 805-808.	3.1	152
28	Stress contributes to the development of central insulin resistance during aging: Implications for Alzheimerâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2332-2339.	3.8	35
29	Mineralocorticoid Receptor Activation Induces Insulin Resistance Through câ€Jun Nâ€terminal kinases in Response to Chronic Corticosterone: Cognitive Implications. Journal of Neuroendocrinology, 2013, 25, 350-356.	2.6	23
30	Mechanisms Involved in BACE Upregulation Associated to Stress. Current Alzheimer Research, 2012, 9, 822-829.	1.4	13
31	Long lasting effects of early-life stress on glutamatergic/GABAergic circuitry in the rat hippocampus. Neuropharmacology, 2012, 62, 1944-1953.	4.1	103
32	Stressâ€induced anhedonia is associated with an increase in Alzheimer's diseaseâ€related markers. British Journal of Pharmacology, 2012, 165, 897-907.	5.4	54
33	Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation. Hippocampus, 2011, 21, 999-1009.	1.9	46
34	Insulin Levels are Decreased in the Cerebrospinal Fluid of Women with Prodomal Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 405-413.	2.6	68
35	Interactions Between Age, Stress and Insulin on Cognition: Implications for Alzheimer's Disease. Neuropsychopharmacology, 2010, 35, 1664-1673.	5.4	109
36	HPA Axis Dysregulation Associated to Apolipoprotein E4 Genotype in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 829-838.	2.6	73

#	Article	IF	Citations
37	Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. International Journal of Neuropsychopharmacology, 2010, 13, 775-784.	2.1	26
38	Altered NCAM Expression Associated with the Cholinergic System in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 659-668.	2.6	38